.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Disease Spotlight: NMOSD

Satralizumab Demonstrates Long-Term Safety in NMOSD

October 28th 2021

Rates of infection or serious infection with satralizumab in the overall treatment period were not higher than those on placebo in the double-blind period and did not increase over time.

New Sponsors, Potential Development in NMOSD: Bruce Cree, MD, PhD, MAS, FAAN

October 24th 2021

Following the approval of 3 treatments for the disease, the clinical research director of the UCSF Multiple Sclerosis Center commented on the implications for the clinical development pipeline. [WATCH TIME: 4 minutes]

Understanding the Value of B-Cell Depletion in NMOSD

October 23rd 2021

Jeffrey Bennett, MD, PhD, professor of neurology, University of Colorado, discussed his presentation at ECTRIMS involving the relationship of B-cell depletion and improved outcomes in patients treated with inebilizumab.

Eculizumab Shows Better Prolonging of Time to NMOSD Relapse Than Other Treatments

October 17th 2021

An indirect comparison study evaluated relative treatment effects of eculizumab (Soliris; Alexion), inebilizumab (Uplizna; Horizon), and satralizumab (Enspryng; Genentech), the 3 FDA-approved options for NMOSD.

Patient Education and Awareness in NMOSD: Bruce Cree, MD, PhD, MAS, FAAN

October 13th 2021

The clinical research director of the USCF Multiple Sclerosis Center discussed the importance of improving knowledge and education for patients with NMOSD, as well as strategies to do so. [WATCH TIME: 3 minutes]

Day-to-Day Care of NMOSD, Advances and Challenges: Bruce Cree, MD, PhD, MAS, FAAN

October 12th 2021

Discussing the 3 FDA-approved treatments for NMOSD, the clinical research director of the UCSF Multiple Sclerosis Center commented on the positive impact, as well as resultant barriers to care. [WATCH TIME: 4 minutes]

Understanding Disadvantages to African Americans in NMOSD Trials: Evanthia Bernitsas, MD

October 12th 2021

The neurologist at Wayne State University provided background on why there needs to be a continued focus on including and studying African American patients with NMOSD in trials. [WATCH TIME 3 minutes]

Treating NMOSD: What to Expect

October 12th 2021

Neuromyelitis optica patient Doug highlights the types of treatments he has received since his diagnosis and provides suggestions to patients on navigating therapy, especially during the COVID-19 pandemic.

Navigating NMOSD Infusion-Based Treatment

October 12th 2021

Kim, a patient with neuromyelitis optica, describes what it has been like receiving rituximab infusions as preventive therapy, and shares advice for others who are about to embark on a similar treatment journey.

Recent Advances and New Therapies for NMOSD: Bruce Cree, MD, PhD, MAS, FAAN

October 11th 2021

The clinical research director of the UCSF Multiple Sclerosis Center provided an overview on the state of care for NMOSD, specifically the development of inebilizumab, satralizumab, and eculizumab. [WATCH TIME: 6 minutes]